The need for a sequencing-based assay to supplement the Abbott m2000 RealTime HCV Genotype II assay: A 1 year analysis

Benedet, Marlin; Adachi, Dena; Wong, Anita; Wong, Sallene; Tellier, Raymond; Tang, Julian W.

doi:10.1016/j.jcv.2014.04.005

Cited by 29 publications

(18 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(3) We replicated the association of the T allele of rs3747517 (H843) with SC (odds ratio [OR] of SC for T/T vs. T/C [or T/C vs. C/C] 5 1.44; 95% confidence interval [CI]: 1.0-2.13; P one-sided 5 0.03; Fig. 1A).…”

Section: To the Editormentioning

confidence: 53%

“…The overall percentage of genotype/subtype resolved by direct sequencing in the current study is similar to what has been found in other recent publications. (3,5) Our results emphasize the importance of dedicating time and effort for a proper genotype/subtype assignment before starting therapy. HCV sequencing allows precise subtype/genotype assignment, along with evaluation of natural resistance, thus reducing the risk of failure, especially in difficult-to-treat patients.…”

Section: To the Editormentioning

confidence: 62%

“…In addition, two assays (Abbott RealTime HCV Genotype II and Versant HCV genotyping 2.0) also target the nonstructural (NS)5b and core genes, respectively, allowing a potentially more precise subtype discrimination within genotypes. (3) Nevertheless, in daily clinical practice, indeterminate, mixed, and unspecified subtype results are frequently observed.…”

Section: To the Editormentioning

confidence: 99%

“…(3) In order to define the extent of this unmet clinical need, we reanalyzed genotype data by phylogenetic analysis of 343 HCV-infected patient candidates to DAA treatment who performed a genotypic resistance test between 2011 and 2014. To confirm the appropriate genotype allocation, HCV sequencing was performed by homemade protocols, specific for each genotype, on NS3 protease (95% samples), together with/in alternative to NS5A (9%) and/or NS5B (14%).…”

Section: To the Editormentioning

confidence: 99%

See 3 more Smart Citations

Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents

Ceccherini‐Silberstein

Maio

Aragri

et al. 2015

Hepatology

View full text Add to dashboard Cite

show abstract

Section: To the Editormentioning

confidence: 53%

Section: To the Editormentioning

confidence: 62%

Section: To the Editormentioning

confidence: 99%

Section: To the Editormentioning

confidence: 99%

See 2 more Smart Citations

Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents

Ceccherini‐Silberstein

Maio

Aragri

et al. 2015

Hepatology

View full text Add to dashboard Cite

show abstract

“…Therefore, in order to genotype a sample we usually use PCR to amplify a highly preserved region in the HCV genome, namely non-coding region 5' or 5'-UTR. Furthermore, commercial essays have been developed in the last few years that may perform genotyping depending on differences in region NS5b (10). However, despite advances in HCV genotyping, the inability to genotype or subtype a sample is not uncommon.…”

Section: Genotyping Errorsmentioning

confidence: 99%

Causes of treatment failure for hepatitis C in the era of direct-acting antiviral therapy

Cabezas¹,

Llerena²,

Puente³

et al. 2015

Rev Esp Enferm Dig

View full text Add to dashboard Cite

Hepatitis C therapy in the era of the newer direct-acting antiviral agents has radically changed our treatment schemes by achieving very high rates of sustained virological response. However, treatment with direct antiviral agents fails in a subgroup of patients. This group of so-called difficult-to-treat individuals is the subject of this paper, which reviews the causes of virological failure, their clinical implications, and some final recommendations.

show abstract

Indeterminate genotypes of hepatitis C virus by the Abbott RealTime HCV Genotype II assay in Morocco. About eight cases resolved by a sequencing method

Mesbahi

Kabbaj

Malki

et al. 2018

Journal of Medical Virology

View full text Add to dashboard Cite

The early detection and genotyping of the hepatitis C virus (HCV) are important in the management of this infection. The genotype is the major factor influencing treatment decisions. That's why it is necessary to use fast and accurate methods in its determination. This study reports, over a period of 3 years (from May 2012 to July 2015), the percentage of indeterminate genotypes by the Abbott RealTime HCV Genotype II test and their results using a sequencing technique. Of 309 samples of 309 patients tested, 11 were indeterminate (4.4%). There were three cases of cross-reactivity (1b/4 in one case, 2/5 in two cases) and a possible co-infection 1 + 4. Among those indeterminate genotypes, cross-reactivities and co-infections, ten samples were tested by sequencing. The results were for four of them a 1d subtype, five were a 2i subtype and one was a 2l subtype. These results support the thesis of complementarity between the two methods: genotyping for the detection of mixed reactions and sequencing for resolving indeterminate cases by genotyping.

show abstract

The need for a sequencing-based assay to supplement the Abbott m2000 RealTime HCV Genotype II assay: A 1 year analysis

Cited by 29 publications

References 13 publications

Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents

Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents

Causes of treatment failure for hepatitis C in the era of direct-acting antiviral therapy

Indeterminate genotypes of hepatitis C virus by the Abbott RealTime HCV Genotype II assay in Morocco. About eight cases resolved by a sequencing method

Contact Info

Product

Resources

About